OptiNose (OPTN) Announces XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Visit StreetInsider.com at http://www.streetinsider.com/Trading+Halts/OptiNose+%28OPTN%29+Announces+XHANCE+Approved+by+FDA+as+First+and+Only+Medication+Indicated+for+Treatment+of+Adults+with+Chronic+Rhinosinusitis+without+Nasal+Polyps/22938534.html for the full story.

Leave a Reply

Your email address will not be published. Required fields are marked *